Clinical trial · Observational
Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces
T-Staging Strategies and Their Prognostic and Therapeutic Significance in Lung Cancer With Cystic Airspaces: A Retrospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to determine the most accurate tumor size measurement method for T-staging and prognostic assessment in lung cancer with cystic airspaces (LCCA). The main questions it aims to answer are: * What is the optimal T-staging approach for accurately classifying lung cancer with cystic airspaces （LCCA) and predicting patient outcomes? * How do imaging features of cystic lesions correlate with their pathological characteristics? * What is the relationship between imaging features of cystic airspace-associated lesions and patient prognosis? * Can optimizing the T-staging method improve clinical decision-making in patients with LCCA?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer Associated With Cystic Airspaces | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (3)
- label
- group 1
- description
- radiologic T stage based on the maximum tumor diameter including cystic components
- label
- group 2
- description
- radiologic T stage based on the diameter of the solid/invasive portion only
- label
- group 3
- description
- pathologic T stage derived from the resected specimen
Primary outcomes (2)
- measure
- DFS
- timeFrame
- From enrollment to the end of surgery for 5 years
- description
- Disease-Free Survival
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed non-small cell lung cancer (NSCLC), as verified by biopsy or postoperative pathological examination; 2. Patients who have undergone surgical lung resection; 3. Patients with complete preoperative chest CT imaging data; 4. Preoperative chest CT showing a well-defined gas-containing (air-filled) cystic component within the tumor. Exclusion Criteria: 1. History of pulmonary diseases that could produce cystic lung lesions (e.g., tuberculosis, pulmonary fungal infections, bullae, emphysema, Lymphangioleiomyomatosis \[LAM\], or Birt-Hogg-Dubé \[BHD\] syndrome); 2. Systemic anti-tumor therapies, including chemotherapy, radiotherapy, or targeted therapies (such as monoclonal antibodies, small-molecule tyrosine kinase inhibitors, among others), were administered prior to enrollment; 3. Patients with concurrent other malignancies; 4. Patients with missing or poor-quality preoperative chest CT imaging data.
References
Publications (0)
Data not yet available